Physician profile
Cibu Panicker
NPI 1235492760
$1,562.78
in general payments reported to CMS, 2019-2025
20 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.66 · 2021: $66.56 · 2022: $204 · 2023: $171 · 2024: $376 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $219.39 | 2024-2025 | |
| Lilly USA, LLC | $193.56 | 2024-2025 | Zepbound, Mounjaro |
| Dexcom, INC. | $173.67 | 2021-2025 | Dexcom G6 Transmitter |
| Indivior INC. | $147.24 | 2022-2025 | Sublocade |
| Organon LLC | $118.87 | 2021-2025 | Nexplanon |
| Pfizer INC. | $94.81 | 2021-2025 | |
| Cranial Technologies, INC | $90.92 | 2022-2025 | Doc Band |
| Hologic Sales and Service, LLC | $74.18 | 2024-2025 | Aptima |
| Novo Nordisk INC | $72.68 | 2024-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $65.88 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Glaxosmithkline, LLC. | $55.95 | 2022-2025 | Shingrix, Arexvy |
| Abbvie INC. | $55.42 | 2022 | |
| Corcept Therapeutics | $32.98 | 2025 | Korlym |
| Sanofi Pasteur INC. | $32.12 | 2019-2022 | |
| Gilead Sciences, INC. | $28.91 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $26.43 | 2025 | Talicia |
| Viiv Healthcare Company | $24.81 | 2025 | Apretude |
| Astellas Pharma US INC | $20.03 | 2024 | Veozah |
| Abbott Laboratories | $18.78 | 2023 | Freestyle Libre 2 |
| Lucid Diagnostics INC. | $16.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cibu Panicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.